Phase 3
Completed N=105
Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Source: ClinicalTrials.gov NCT02023268 ↗Enrolled (actual)
105
Serious AEs
0.0%
Results posted
Apr 2016
Primary outcomePrimary: Global Ocular Staining (With Oxford Scale - Ranges : 0-15) — -2.5; -2.7 score on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Comparison of the efficacy and safety of T2762 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Global Ocular Staining (With Oxford Scale - Ranges : 0-15) |
-2.5; -2.7 | — |
Eligibility Criteria
Inclusion Criteria
- Signed and dated informed consent
- Male or female aged from ≥ 18 years old.
- Known Dry Eye Syndrome requiring artificial tears within the last 3 months prior to study selection.
Exclusion Criteria
- Best far corrected visual acuity < 1/10
- Severe blepharitis
- Severe Dry Eye
Data sourced from ClinicalTrials.gov (NCT02023268). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.